The KRAS mutation, a main carcinogenesis driver that has been extensively investigated in the last 30 years, is involved in ~90% of pancreatic cancer, 40% of colon cancer, and 20–30% of lung cancer [10]. Here, KRAS is linked to familial pancreatic carcinoma.